Published 1 year ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Summary by Ground News

Shares of Kala Pharmaceuticals Inc. KALA, +1.03% shot up 45.7% in premarket trading Wednesday. The company said the Food and Drug Administration accepted its investigational new drug (IND) application for KPI-012, its treatment of persistent corneal epithelial defect (PCED)

0 Articles

All

Left

Center

Right

CBS News

Kala Pharmaceuticals shares soar after FDA approves trial for drug to treat PCED

Biotech firm developing potential treatment for rare eye disease called "persistent corneal epithelial defect."

1 year ago

Read Full Article

MarketWatch

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Shares of Kala Pharmaceuticals Inc. shot up 45.7% in premarket trading Wednesday, after the biopharmaceutical company said the Food and Drug Administration...

1 year ago·United States

Read Full Article

Spotlight Growth

Kala Pharmaceuticals (NASDAQ: KALA) Says FDA Accepted its IND Application for KPI-012 and Treatment of PCED

Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and

1 year ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left1Leaning Right0Center1Last Updated1 year agoBias Distribution

50% Left, 50% Center

Bias Distribution

50% of the sources lean Left, 50% of the sources are Center

50% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

0 Articles

0 Articles

Kala Pharmaceuticals shares soar after FDA approves trial for drug to treat PCED

Kala Pharmaceuticals shares soar after FDA approves trial for drug to treat PCED

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Kala Pharmaceuticals (NASDAQ: KALA) Says FDA Accepted its IND Application for KPI-012 and Treatment of PCED

Kala Pharmaceuticals (NASDAQ: KALA) Says FDA Accepted its IND Application for KPI-012 and Treatment of PCED

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics